NVO

Novo Nordisk A/S Form 20-F Summary (Fiscal Year 2018)

Business Context and Reporting Period

This Form 20-F is an annual report for Novo Nordisk A/S, a Danish global healthcare company and world leader in diabetes care, for the fiscal year ended December 31, 2018. The company operates two primary segments: Diabetes and Obesity (insulin, GLP-1, anti-obesity) and Biopharmaceuticals (haemophilia, growth hormone, hormone replacement). Financial statements are prepared in accordance with International Financial Reporting Standards (IFRS) and reported in Danish kroner (DKK).

Key Financial Metrics

Debt and Liquidity: No long-term loans were outstanding as of December 31, 2018. Current debt was minimal (DKK 515 million). Financial resources (cash, bonds, undrawn credit facilities less current debt) totaled DKK 26,697 million. The company maintains a strong liquidity position with no material restrictions on fund transfers.

Material Changes vs. Prior Period

• Revenue: Reported net sales remained flat at DKK 111.8 billion (0% growth) compared to 2017. However, sales growth in local currencies was 5%, indicating a negative impact from foreign exchange rates (specifically a stronger DKK).
• Profitability: Operating profit decreased by 4% to DKK 47.2 billion, while Net Profit increased slightly by 1% to DKK 38.6 billion. Operating profit growth in local currencies was 3%.
• Product Performance:
  • Diabetes & Obesity: Victoza sales increased 5% (DKK) and 9% (local currency). Ozempic (once-weekly GLP-1) generated DKK 1,796 million in sales in its first full year of launch.
  • Biopharmaceuticals: NovoSeven sales decreased due to intensified competition in North America, partially offset by growth in NovoEight.
• Share Repurchases: The company completed a DKK 15 billion share repurchase program in 2018, purchasing approximately 50.8 million shares.

Guidance, Outlook, and Risks

Outlook: Management expects average prices after rebates in the United States to decline further in 2019, driven by the basal insulin segment and Medicare Part D coverage gap funding changes, with an estimated negative impact of approximately DKK 2 billion. Capital expenditure for 2019 is expected to be around DKK 9.0 billion, primarily for capacity expansion in diabetes care.

Risks and Contingencies:

• Brexit: Uncertainty regarding the UK's exit from the EU poses risks to supply chains, regulatory alignment, and costs. A "No-Deal" scenario could incur additional costs for personnel, batch tracing, and customs duties.
• Cybersecurity: The company faces risks from IT system disruptions and data breaches, which could impact operations and reputation.
• Pricing Pressure: Continued pressure from payers and pharmacy benefit managers (PBMs) in the US to increase rebates and reduce drug costs.
• Patent Expirations: Key products like Levemir face patent expirations in 2019 in major markets (US, Europe, Japan), though biosimilar pathways for insulin are complex.

Key Facts for Investor Verification

• Dividend Payout: Total dividend for 2018 is DKK 8.15 per share (interim DKK 3.00 + proposed final DKK 5.15), representing a payout ratio of 50.6%.
• Ownership Structure: The Novo Nordisk Foundation (via Novo Holdings A/S) holds all A shares (approx. 74% of voting rights) and a minority of B shares, ensuring stable control.
• Iran Transactions: The company disclosed limited business activities in Iran (gross revenue under DKK 700 million) involving distribution and manufacturing, compliant with Section 13(r) of the Exchange Act.
• Non-IFRS Measures: Investors should note the reconciliation of "Free Cash Flow" and "Cash to Earnings" (84.2% in 2018) as key management metrics.
• Regulatory Compliance: The company is a "controlled company" under NYSE rules due to the Foundation's majority voting power, exempting it from certain corporate governance requirements (e.g., majority independent directors).